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OBJECTIVE — Thisstudytestedthehypothesisthatphosphodiesterase5inhibitionaloneor
in combination with ACE inhibition improves glucose homeostasis and ﬁbrinolysis in individ-
uals with metabolic syndrome.
RESEARCH DESIGN AND METHODS — Insulin sensitivity, -cell function, and ﬁ-
brinolytic parameters were measured in 18 adults with metabolic syndrome on 4 separate days
after a randomized, crossover, double-blind, 3-week treatment with placebo, ramipril (10 mg/
day), tadalaﬁl (10 mg o.d.), and ramipril plus tadalaﬁl.
RESULTS — Ramipril decreased systolic and diastolic blood pressure, ACE activity, and
angiotensin II and increased plasma renin activity. Ramipril did not affect insulin sensitivity or
-cell function. In contrast, tadalaﬁl improved -cell function (P  0.01). This effect was
observed in women (331.9  209.3 vs. 154.4  48.0 32    mmol
1   l
1, respectively, for
tadalaﬁl treatment vs. placebo; P  0.01) but not in men. There was no effect of any treatment
on ﬁbrinolysis.
CONCLUSIONS — Phosphodiesterase 5 inhibition may represent a novel strategy for im-
proving -cell function in metabolic syndrome.
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M
etabolic syndrome affects over
20% of U.S. adults, predicts dia-
betes, and will soon overtake
smoking as the premier cardiovascular
risk factor (1). Progression to type 2 dia-
betes results from impaired insulin sensi-
tivity and pancreatic -cell dysfunction
(2,3). ACE inhibitors (ACEIs) and angio-
tensin receptor blockers (ARBs) may de-
crease diabetes in high-risk individuals
(4). These agents can improve insulin sen-
sitivity by preventing inhibitory effects of
angiotensin II on GLUT4 translocation (5)
or improve insulin secretion by preventing
angiotensin II type 1 receptor–dependent
inhibition of insulin release (6).
Nitric oxide (NO) may also contrib-
ute to salutary effects of ACEIs and ARBs
on glucose homeostasis (7). NO stimu-
lates muscle glucose uptake through cy-
clic guanosine monophosphate (cGMP)
(7). In mice, inhibiting cGMP degrada-
tion by phosphodiesterase 5 increases in-
sulin sensitivity and muscle glucose
uptake (8). cGMP decreases apoptosis
and increases intracellular calcium in
pancreatic -cells, suggesting an insuli-
notropic effect (9,10). We tested the hy-
pothesis that decreasing degradation of
cGMP would enhance any effect of ACE
inhibition on insulin sensitivity or -cell
function in humans.
RESEARCH DESIGN AND
METHODS— Subjects with meta-
bolicsyndrome(NationalCholesterolEd-
ucationProgramcriteria)participatedina
double-blind, randomized, and placebo-
controlled crossover study.
Each subject was studied four times
(see supplementary Fig. A1, available in
an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc08-
1862/DC1). Antihypertensive medications
were withdrawn 3 weeks before the study.
Participants were then randomized to one
of four 3-week treatments (placebo plus
placebo,ramipril[10mg/day]plusplacebo,
tadalaﬁl [10 mg o.d.] plus placebo, and
ramipril plus tadalaﬁl) separated by a
1-week washout period.
During the last week of treatment,
subjects ate a nitrate-, sodium-, and calo-
rie-controlled diet. On the last day, they
collected a 24-h urine sample and fasted
overnight. At 0730 h, supine blood pres-
sure and heart rate were measured thrice,
2 min apart. Blood was drawn via venous
catheter for plasma renin activity (PRA),
ACE activity, angiotensin II, aldosterone,
ﬁbrinolytic parameters, NO metabolites,
L-citrulline, L-arginine, and cGMP.
At 0800 h, subjects underwent a fre-
quently sampled intravenous glucose
tolerance test (additional information
available in the online appendix). Insulin
sensitivity index, glucose effectiveness in-
dex, homeostasis model assessment of in-
sulin resistance, and -cell function were
calculated using a modiﬁed version of
minimal model (MINMOD) formulas.
Acute insulin response to glucose (AIRg)
was assessed from the area under the in-
sulin curve for the ﬁrst 10 min following
dextrose infusion. Because AIRg disre-
gards changes in insulin sensitivity, we
used disposition index, calculated from
insulin sensitivity and AIRg, as a more re-
liable indicator of -cell function (2).
RESULTS— Eighteen subjects com-
pleted the study. Characteristics can be
found in supplementary Tables A1 and A2.
Hemodynamic and renin-angiotensin
effects
Sodium excretion was similar during all
treatments (supplementary Table A3).
Ramipril signiﬁcantly increased PRA and
decreased ACE activity and angiotensin
II (supplementary Table A3). Tadalaﬁl
did not affect the renin-angiotensin-
aldosterone system or alter effects of
ramipril.
Ramipril reduced systolic (P  0.01)
(Fig. 1) and diastolic blood pressure (P 
0.001). Tadalaﬁl did not affect blood
pressure but tended to enhance the
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(P  0.06 for interaction, controlling for
sex and race). No treatments impacted
heart rate.
Glucose homeostasis
Neither ramipril nor tadalaﬁl affected in-
sulin sensitivity (Fig. 1). No treatments
alteredglucoseeffectiveness,ameasureof
insulin-independent glucose disposal
(0.0170.006,0.0170.008,0.017
0.009, and 0.015  0.007 min
1 for pla-
cebo,tadalaﬁl,ramipril,andramiprilplus
tadalaﬁl, respectively).
Ramipril did not affect -cell func-
tion.Incontrast,tadalaﬁlsigniﬁcantlyim-
proved -cell function after controlling
for sex (P  0.01) (Fig. 1) or baseline
fasting glucose (P  0.05). In a subgroup
analysis, tadalaﬁl improved -cell func-
tion in women (154.4  48.0, 331.9 
209.3, 229.1  202.1, and 259.7  95.8
 mmol
1 l
1duringplacebo,tadalaﬁl,
ramipril, and ramipril plus tadalaﬁl treat-
ment, respectively; P  0.01 for tadalaﬁl
effect) but not in men. There was a trend
toward improved -cell function during
tadalaﬁl treatment in individuals with
baseline fasting hyperglycemia (195.3 
103.1, 278.7  114.0, 157.2  52.6,
and210.6  72.3    mmol
1   l
1 dur-
ing placebo, tadalaﬁl, ramipril, and
ramipril plus tadalaﬁl treatment, re-
spectively; P  0.06 for tadalaﬁl) but
not in subjects with normal fasting glu-
cose. There was no effect of race and no
interactive effect of ramipril or tadalaﬁl
on -cell function.
Ramipril(P0.02)andtadalaﬁl(P
0.02) improved the disposition index in
women but not in men after controlling
for fasting glucose. This was attributable
to a synergistic effect of ramipril and
tadalaﬁl on the disposition index
(1,001.8  909.5, 977.8  728.5,
1,308.8  976.2, and 1,982.2  1,982.2
units during placebo, tadalaﬁl, ramipril,
and ramipril plus tadalaﬁl, respectively;
P  0.05 for ramipril plus tadalaﬁl).
CONCLUSIONS — The phosphodi-
esterase 5 inhibitor tadalaﬁl, alone or in
combination with ramipril, improved
basal and glucose-stimulated -cell func-
tion. The latter effect was independent of
insulin sensitivity, as indicated by im-
provement in the disposition index (2).
Metabolic syndrome, an insulin-
resistant state, frequently progresses to
type 2 diabetes. Loss of -cell function
andimpairedinsulinsensitivitybothcon-
tributetothedevelopmentofdiabetes(2).
-Celldysfunctionmayplayagreaterrole
Figure 1—Effect of treatment on systolic blood pressure (BP), diastolic blood pressure, insulin sensitivity, and -cell function. Sex and race were
included as covariates in the ANOVA. For -cell function, data are presented as estimated marginal means after controlling for sex.
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creatic -cell apoptosis precedes overt di-
abetes in high-risk individuals (10) and
surgical reduction of pancreatic mass
causesimpairedglucosetoleranceanddi-
abetes (11).
Toourknowledge,nopriorhumanor
animal studies have reported an effect of
phosphodiesterase 5 inhibition on -cell
function.Pancreatic-cellsexpressendo-
thelialNOsynthase(12).Previousstudies
provide conﬂicting data, however, re-
garding the effect of NO on -cell func-
tion, with some suggesting that NO
suppresses insulin secretion (13,14) and
others indicating that NO enhances insu-
lin secretion (12,15).
Tadalaﬁl improved islet cell function
in women studied but not in men. A
higher frequency of fasting hyperglyce-
mia among women with metabolic syn-
drome may have confounded this sex
difference. Alternatively, women may be
more sensitive than men to decreased
cGMPdegradation.Insupportofthispos-
sibility, three of six women studied, but
no men, reported muscle aches during
tadalaﬁl treatment.
ACEIs improve glucose homeostasis
or decrease diabetes incidence in clinical
trials (4). Although ACEIs and ARBs im-
prove glucose uptake and/or insulin se-
cretion in vitro and in rodents, studies in
humans provide mixed data regarding
their effects on insulin resistance (4). We
did not detect an effect of ramipril on in-
sulin sensitivity or -cell function but did
detect an effect of ramipril on disposition
index in women. Tadalaﬁl enhanced this
effect, again suggesting cGMP-dependent
improvement in insulin secretion.
Tadalaﬁl improves -cell function
in metabolic syndrome. Studies are
needed to determine whether the effect
of tadalaﬁl is limited to women or related
to the magnitude of hyperglycemia.
Given the increasing role attributed to
-cell dysfunction in the pathogenesis
of type 2 diabetes, these data suggest a
novel therapeutic intervention in a
high-risk population.
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